TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18277670

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g in 250 ml normal saline, infused before tourniquet deflation and again 3 hours later)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal saline (250 ml infused intravenously)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tranexamic acid and Normal saline
Number of subjects: 102
Study: 15277964

Group type: EXPERIMENTAL
Intervention: Rehabilitation (physical and occupational therapy sessions five times per week for 24.8 +/- 8.1 days)
Number of subjects: 30
Study: 12195325

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic stent shunt (TIPS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) plus propranolol
Number of subjects: 85
Study: 9807208

Group type: EXPERIMENTAL
Intervention: Intensive preoperative radiotherapy (IPRT)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Intensive preoperative radiotherapy (IPRT) combined with postoperative chemo- and hormonal therapy
Number of subjects: 423
Study: 7815697

Group type: EXPERIMENTAL
Intervention: Continuous interpleural infusion of 0.5% bupivacaine at the rate of 5 ml.h‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.25% bupivacaine and 0.025 buprenorphine at the rate of 1 ml.h‐1
Number of subjects: 20
Study: 2767930

Group type: EXPERIMENTAL
Intervention: Self-rated and teacher-rated questionnaires
Number of subjects: 0
Study: 31988195

Group type: EXPERIMENTAL
Intervention: Logistic regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple linear regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression
Number of subjects: 0
Study: 31112383

Group type: EXPERIMENTAL
Intervention: Cisatracurium continuous infusion (median duration 47.8 hours, median dose 1807 mg) with deep sedation
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Usual-care approach without routine neuromuscular blockade and lighter sedation targets
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Cisatracurium continuous infusion
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Usual-care approach
Number of subjects: 1006
Study: 28492492

Group type: EXPERIMENTAL
Intervention: Whey protein supplement (PRO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Maltodextrin supplement (CHO)
Number of subjects: 84
Study: 26110548

Group type: EXPERIMENTAL
Intervention: Modified Constant Score (CS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oxford Shoulder Score (OSS)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: European Quality of Life‐5 Dimensions‐3 Level (EQ‐5D‐3L) index
Number of subjects: 126
Study: 23375006

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 21967071

Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg/day
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nalmefene 80 mg/day
Number of subjects: 270

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg on day 7
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 19267709

Group type: EXPERIMENTAL
Intervention: Metformin 1 g x two times daily
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Insulin detemir before bedtime
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 before dinner
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Insulin aspart before main meals and insulin detemir before bedtime
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Composite outcome of death, acute myocardial infarction, stroke or amputation
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Average postprandial glucose increment from 0 to 18 months
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia and any inadvertent medical episodes
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Change in plaque formation in the carotids
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Cardiovascular biomarkers
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Body composition
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Progression of microvascular complications
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 950
Study: 16451151

Group type: EXPERIMENTAL
Intervention: Modified reliable change index
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 20% decline on 20% of tasks rule
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 1SD decline on two or more tasks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (healthy non-surgical controls)
Number of subjects: 204
Study: 15491720

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 887

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 887
Study: 11730741

Group type: EXPERIMENTAL
Intervention: Luteal phase support with vaginal progesterone beginning on day 3 after oocyte retrieval
Number of subjects: 126

Group type: COMPARATOR
Intervention: Luteal phase support with vaginal progesterone beginning on day 6 after oocyte retrieval
Number of subjects: 126

Group type: COMPARATOR
Intervention: Luteal phase support with vaginal progesterone beginning on day 6 after oocyte retrieval (GnRH agonist group)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Luteal phase support with vaginal progesterone beginning on day 3 after oocyte retrieval (GnRH agonist group)
Number of subjects: 126
Study: 9203450

Group type: EXPERIMENTAL
Intervention: EM523L
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study: 8382120

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 2.5 pmol/kg/min for 120 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle alone)
Number of subjects: 20
Study: 3303278

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol 400 micrograms once daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol 200 micrograms twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31691579

Group type: EXPERIMENTAL
Intervention: Hypothermically stored amniotic membrane (HSAM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 76
Study: 30285718

Group type: EXPERIMENTAL
Intervention: Implementation facilitation strategy (external facilitation plus QI team)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard VA national support
Number of subjects: 12
Study: 27588541

Group type: EXPERIMENTAL
Intervention: Alcohol-congruent stimuli in a pub context
Number of subjects: 76

Group type: COMPARATOR
Intervention: Alcohol-incongruent stimuli in a lecture context
Number of subjects: 76
Study: 24897738

Group type: EXPERIMENTAL
Intervention: Quadriceps-sparing (QS) technique
Number of subjects: 129

Group type: COMPARATOR
Intervention: Medial parapatellar arthrotomy (MPPA) technique
Number of subjects: 129
Study: 22882572

Group type: EXPERIMENTAL
Intervention: Same-day discharge with remote monitoring for 24 hours after ICD implant
Number of subjects: 71

Group type: COMPARATOR
Intervention: Next-day discharge with overnight in-hospital observation
Number of subjects: 71
Study: 21143399

Group type: EXPERIMENTAL
Intervention: 5% homatropine eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% hypromellose (placebo) eye drops
Number of subjects: 40
Study: 18666018

Group type: EXPERIMENTAL
Intervention: Gelfoam embolization
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional particle embolization
Number of subjects: 54
Study: 16075570

Group type: EXPERIMENTAL
Intervention: School breakfast program (supplemented children)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: School breakfast program with meat
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (children receiving a goat)
Number of subjects: 540
Study: 12383667

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily for bodyweight ≤40 kg; 500 mg daily for bodyweight >40 kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Azithromycin and Placebo
Number of subjects: 41
Study: 12840867

Group type: EXPERIMENTAL
Intervention: Theophylline (Protheo, 400 mg, qd)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8772970

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate 2 gm bolus
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravenous verapamil 5 mg
Number of subjects: 154
Study: 2383413

Group type: EXPERIMENTAL
Intervention: Patient-specific feedback
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reminder checklists
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined interventions (checklists + feedback)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 6259922

Group type: EXPERIMENTAL
Intervention: Liquid glucose formula (75 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brown rice (75 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pinto beans (75 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All Bran (75 g carbohydrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no dietary fiber)
Number of subjects: 8
Study: 31653011

Group type: EXPERIMENTAL
Intervention: Dietary supplement plus physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet and physical activity alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29132930

Group type: EXPERIMENTAL
Intervention: eCRTAF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Conducted AF Response)
Number of subjects: 0
Study: 27283295

Group type: EXPERIMENTAL
Intervention: Internet smoking cessation intervention
Number of subjects: 5290

Group type: COMPARATOR
Intervention: NHIS smokers (control group)
Number of subjects: 5290

Group type: COMPARATOR
Intervention: NHIS subgroup based on Internet use and cessation behavior (control group)
Number of subjects: 5290
Study: 24660837

Group type: EXPERIMENTAL
Intervention: Parenteral n‐3 fatty acids (2 ml/kg/day of a lipid emulsion containing highly refined fish oil for 7 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Parenteral n‐3 fatty acids
Number of subjects: 50
Study: 22681705

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 50
Study: 19083199

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 FORTE (twice a day)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (cellulose-based)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 FORTE
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 17720993

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose Urocortin 2 (25 microg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High dose Urocortin 2 (100 microg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urocortin 2 (100 microg)
Number of subjects: 8
Study: 16633764

Group type: EXPERIMENTAL
Intervention: Preoperative flurbiprofen axetil, 1 mg x kg(‐1)
Number of subjects: 36
Study: 14514944

Group type: EXPERIMENTAL
Intervention: ACBT + NIV
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard treatment (ACBT)
Number of subjects: 26
Study: 10789839

Group type: EXPERIMENTAL
Intervention: Tacalcitol 0.4 microg/g ointment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tacalcitol 4 microg/g ointment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tacalcitol 40 microg/g ointment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 25
Study: 8695107

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms administered through a spinal needle
Number of subjects: 23

Group type: COMPARATOR
Intervention: No intravenous (i.v.) fluid
Number of subjects: 23
Study: 1832500

Group type: EXPERIMENTAL
Intervention: AM3 (a new oral biological response modifier)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral washes (control group)
Number of subjects: 39
Study: 6350411

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg single dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg t.i.d. for 4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment (4 days)
Number of subjects: 11
Study: 31718628

Group type: EXPERIMENTAL
Intervention: Loudspeaker announcements regarding malaria care and prevention practices
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (no loudspeaker announcements)
Number of subjects: 270
Study: 30442234

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU per week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26681392

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF drugs)
Number of subjects: 1183
Study: 25561817

Group type: COMPARATOR
Intervention: MMC group (36 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: TQD group (72 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: TTK group (36 patients)
Number of subjects: 144
Study: 22313454

Group type: EXPERIMENTAL
Intervention: Prophylactic central lymph node dissection
Number of subjects: 5840

Group type: COMPARATOR
Intervention: Control group (no prophylactic central lymph node dissection)
Number of subjects: 5840
Study: 19160408

Group type: EXPERIMENTAL
Intervention: Two applications of Mitomycin-C (MMC) (0.5 mg/mL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: One application of Mitomycin-C (MMC) (0.5 mg/mL)
Number of subjects: 26
Study: 17953883

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 0
Study: 16385651

Group type: EXPERIMENTAL
Intervention: Thiopental (2 mL, 50 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (2 mL)
Number of subjects: 90
Study: 12019581

Group type: EXPERIMENTAL
Intervention: Good dynamic trunk extensor performance
Number of subjects: 535

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 535
Study: 10543285

Group type: EXPERIMENTAL
Intervention: SR 27417A (20 mg, orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8520443

Group type: EXPERIMENTAL
Intervention: AQL (disease-specific quality of life instrument)
Number of subjects: 32

Group type: COMPARATOR
Intervention: SIP (generic quality of life instrument)
Number of subjects: 32
Study: 2182288

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mifepristone (longer treatment)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7404090

Group type: EXPERIMENTAL
Intervention: Prolonged glucagon infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study: 30469089

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Self-Care Management (SCM)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 392
Study: 27806191

Group type: EXPERIMENTAL
Intervention: 100 mg acebilustat
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acebilustat (50 mg and 100 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25022541

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2356
Study: 24057341

Group type: EXPERIMENTAL
Intervention: Tirofiban maintenance infusion for 24 hours
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tirofiban maintenance infusion for 48 hours
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 21477940

Group type: EXPERIMENTAL
Intervention: Concurrent carboplatin/paclitaxel with 74 Gy 3D-CRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent gemcitabine with 74 Gy 3D-CRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-risk group (N3 disease and V20 >38%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment-related pulmonary toxicity
Number of subjects: 0
Study: 19039248

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 plus PLD 30 mg/m(2) every 3 weeks for 6 cycles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Carboplatin AUC 5 plus paclitaxel 175 mg/m(2) every 3 weeks for 6 cycles
Number of subjects: 50
Study: 17460368

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metformin 500-750 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25
Study: 15314865

Group type: EXPERIMENTAL
Intervention: Perftoran (PF)
Number of subjects: 74
Study: 11723588

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9684138

Group type: EXPERIMENTAL
Intervention: Postoperative transarterial infusion chemotherapy (PTIC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 38
Study: 7889228

Group type: EXPERIMENTAL
Intervention: Crossover designs with three or more treatment periods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interposing sufficiently long 'washout' periods between successive treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current model for crossover trials
Number of subjects: 0
Study: 2904826

Group type: EXPERIMENTAL
Intervention: Cicloprolol 50 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cicloprolol 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31021833

Group type: EXPERIMENTAL
Intervention: Post‐pancreatitis diabetes mellitus (PPDM)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 959
Study: 26496368

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 80
Study: 23095990

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (Pico)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Overall tolerability
Number of subjects: 634
Study: 22007013

Group type: EXPERIMENTAL
Intervention: Hypotonic PMS (0.45% saline)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Isotonic PMS (0.9% saline)
Number of subjects: 258
Study: 18091334

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy plus carboplatin 100 mg/m intravenously once weekly during radiation (arm B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone (arm A)
Number of subjects: 72
Study: 16110522

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 14533615

Group type: EXPERIMENTAL
Intervention: Ezetimibe alone or added to existing statin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe alone or combined with a statin
Number of subjects: 0
Study: 14618039

Group type: EXPERIMENTAL
Intervention: AAI right atrial pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bachmann's bundle pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triggered mode pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial overdrive algorithms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant beta-blocker use
Number of subjects: 0
Study: 10451163

Group type: EXPERIMENTAL
Intervention: 0, 1, and 6 months vaccination schedule
Number of subjects: 800

Group type: COMPARATOR
Intervention: 0, 1, and 12 months vaccination schedule
Number of subjects: 800
Study: 9620063

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2565093

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Famotidine and Ranitidine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Other groups (not specified)
Number of subjects: 93
Study: 941865

Group type: EXPERIMENTAL
Intervention: Three levels of nitrogen intake; specific dosages not mentioned; duration of study not specified.
Number of subjects: 0
Study: 30325889

Group type: EXPERIMENTAL
Intervention: Actual SMT
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham SMT
Number of subjects: 37
Study: 27497847

Group type: EXPERIMENTAL
Intervention: Rescue group (pLVAD insertion due to hemodynamic collapse)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pre-emptive group (pre-ablation pLVAD insertion)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Non-pLVAD group (no pLVAD insertion)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Pre-emptive group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-pLVAD group
Number of subjects: 93
Study: 25665612

Group type: EXPERIMENTAL
Intervention: Xuebijing injection (50 mL added with 100 mL of 0.9% sodium chloride injection, twice a day for 5 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 66
Study: 22951334

Group type: EXPERIMENTAL
Intervention: Involuntary medication as the first choice intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seclusion as the first choice intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involuntary medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seclusion
Number of subjects: 0